Salivary and serum cathelicidin LL-37 levels in subjects with rheumatoid arthritis and chronic periodontitis.

Cheah CW, Al-Maleki AR, Vadivelu J, Danaee M, Sockalingam S, Baharuddin NA, Vaithilingam RD

International journal of rheumatic diseases2 Aug 2020Cited by 14 (Europe PMC)

PMID32743970DOI10.1111/1756-185x.13919PepBankPUB-32743970

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Natural levels measured7

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In people with rheumatoid arthritis and chronic periodontitis, salivary LL‑37 was higher than in non-RA gingivitis and non-RA healthy subjects.
In plain wordsNatural LL‑37 in saliva was higher in people with arthritis and gum disease than in people without arthritis who had gingivitis or healthy gums.
Peptide
LL-37
Outcome
IncreaseSalivary LL-37 in RA with chronic periodontitis
Study
n: not reported in source
Comparator
NRA-G and NRA-H
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
For salivary LL-37, RA-CP was significantly higher than NRA-G and NRA-H (P = .047).
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects were allocated into RA (n = 49) or non-RA (NRA) (n = 55) groups, where 3 subgroups were further established; chronic periodontitis (CP), gingivitis (G) and periodontal health (H).
This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3274397001
02HumanEndogenous levelObservational studyOther
Serum LL‑37 was higher in all RA subjects and in non-RA chronic periodontitis than in non-RA gingivitis and non-RA healthy subjects.
In plain wordsNatural LL‑37 in blood was higher in people with arthritis, and in people with gum disease only, than in those with gingivitis or healthy gums.
Peptide
LL-37
Outcome
IncreaseSerum LL-37 in RA and NRA-CP
Study
n: not reported in source
Comparator
NRA-G and NRA-H
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
For serum LL-37, all RA and NRA-CP were significantly higher than NRA-G and NRA-H (P = .024).
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects were allocated into RA (n = 49) or non-RA (NRA) (n = 55) groups, where 3 subgroups were further established; chronic periodontitis (CP), gingivitis (G) and periodontal health (H).
This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3274397002
03HumanEndogenous levelObservational studyOther
Salivary LL‑37 correlated negatively with clinical attachment loss.
In plain wordsLower natural LL‑37 in saliva was linked to more gum attachment loss.
Peptide
LL-37
Outcome
DecreaseSalivary LL-37 correlation with clinical attachment loss
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Salivary LL-37 correlated negatively with clinical attachment loss (CAL) (P = .048), but positively with erythrocyte sedimentation rate (ESR) in RA-H (P = .045).
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects were allocated into RA (n = 49) or non-RA (NRA) (n = 55) groups, where 3 subgroups were further established; chronic periodontitis (CP), gingivitis (G) and periodontal health (H).
This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3274397003
04HumanEndogenous levelObservational studyOther
In RA subjects with healthy periodontium, salivary LL‑37 correlated positively with erythrocyte sedimentation rate.
In plain wordsIn people with arthritis and healthy gums, higher natural LL‑37 in saliva was linked to a higher inflammation blood marker.
Peptide
LL-37
Outcome
IncreaseSalivary LL-37 correlation with ESR in RA-H
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Salivary LL-37 correlated negatively with clinical attachment loss (CAL) (P = .048), but positively with erythrocyte sedimentation rate (ESR) in RA-H (P = .045).
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects were allocated into RA (n = 49) or non-RA (NRA) (n = 55) groups, where 3 subgroups were further established; chronic periodontitis (CP), gingivitis (G) and periodontal health (H).
This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3274397004
05HumanEndogenous levelObservational studyOther
In RA subjects with gingivitis, serum LL‑37 correlated positively with erythrocyte sedimentation rate.
In plain wordsIn people with arthritis and gingivitis, higher natural LL‑37 in blood was linked to a higher inflammation blood marker.
Peptide
LL-37
Outcome
IncreaseSerum LL-37 correlation with ESR in RA-G
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Serum LL-37 showed positive correlation with ESR (P = .037) in RA-G, with C-reactive protein (P = .017) in RA-H, but negative correlation with number of teeth (P = .002) in NRA-CP.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects were allocated into RA (n = 49) or non-RA (NRA) (n = 55) groups, where 3 subgroups were further established; chronic periodontitis (CP), gingivitis (G) and periodontal health (H).
This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3274397005
06HumanEndogenous levelObservational studyOther
In RA subjects with healthy periodontium, serum LL‑37 correlated positively with C-reactive protein.
In plain wordsIn people with arthritis and healthy gums, higher natural LL‑37 in blood was linked to higher C-reactive protein.
Peptide
LL-37
Outcome
IncreaseSerum LL-37 correlation with CRP in RA-H
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Serum LL-37 showed positive correlation with ESR (P = .037) in RA-G, with C-reactive protein (P = .017) in RA-H, but negative correlation with number of teeth (P = .002) in NRA-CP.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects were allocated into RA (n = 49) or non-RA (NRA) (n = 55) groups, where 3 subgroups were further established; chronic periodontitis (CP), gingivitis (G) and periodontal health (H).
This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3274397006
07HumanEndogenous levelObservational studyOther
In non-RA subjects with chronic periodontitis, serum LL‑37 correlated negatively with the number of teeth.
In plain wordsIn people without arthritis who had gum disease, higher natural LL‑37 in blood was linked to fewer teeth.
Peptide
LL-37
Outcome
DecreaseSerum LL-37 correlation with number of teeth in NRA-CP
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Serum LL-37 showed positive correlation with ESR (P = .037) in RA-G, with C-reactive protein (P = .017) in RA-H, but negative correlation with number of teeth (P = .002) in NRA-CP.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects were allocated into RA (n = 49) or non-RA (NRA) (n = 55) groups, where 3 subgroups were further established; chronic periodontitis (CP), gingivitis (G) and periodontal health (H).
This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3274397007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:57 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.